Trevi Therapeutics, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Trevi Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -51.93, a change of -37.86 year-over-year.
- Trevi Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -33.56.
- Trevi Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -37.55.
- Trevi Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -25.61.
- Trevi Therapeutics, Inc. pe ratio for fiscal 2026 was -51.93.
- Trevi Therapeutics, Inc. pe ratio for fiscal 2025 was -37.55.
- Available history
- 2025-06-30 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |